MHRA restricts quinine use

The MHRA has issued guidance that quinine should not be considered a routine treatment for nocturnal leg cramps.

Although generally well tolerated, its efficacy is modest and a small number of deaths linked to thrombocytopenia has been reported.

Quinine should now only be considered where cramps are very painful and frequent, where other treatable causes of leg cramp have been ruled out and where non-pharmacological measures (e.g. passive stretching exercise) have proved ineffective. The risks should be carefully considered relative to the potential benefits. It should not be prescribed for anyone who has had a previous reaction to quinine including that found in beverages.

It may take up to four weeks for a reduction in frequency of leg cramps to become evident, and the drug should be discontinued at this time if there is no improvement in symptoms or if there is evidence of adverse effects, most notably impaired hearing.

Patients should be advised to report any signs of thrombocytopenia such as unexplained petechiae, bruising or bleeding and not to exceed the recommended dose.

Further information: MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Close-up image of a COVID-19 antibody

Suspending methotrexate therapy shown to improve COVID booster response

Findings from a recent study showed that a two-week...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...